Monoclonal B-cell lymphocytosis or MBL and a n... - CLL Support

CLL Support

23,088 members39,652 posts

Monoclonal B-cell lymphocytosis or MBL and a new clinical trial for those resistant to ibrutinib and more

bkoffman profile image
bkoffmanCLL CURE Hero
0 Replies

Hi,

This week I'm posting an interview that took place at ASH 2016 with Dr. Neil Kay from the Mayo Clinic in Rochester, MN where we discussed monoclonal B-cell lymphocytosis or MBL, which is felt to be a precursor to CLL. You can view my summary, and watch the interview here: cllsociety.org/2017/06/mbl-...

I have posted interviews and articles about research that is being conducted to study treatment options for patients with relapsed or refractory CLL. On occasion I want to make everyone aware of a clinical trial that is starting that might be of interest. I have posted some information about a trial for patients with relapsed refractory CLL who have received 2 or more prior treatments, including treatment with a BTK inhibitor such as ibrutinib or acalabrutinib. You can read more about it here: cllsociety.org/2017/06/new-... It involves the new Sunesis drug that binds differently to BTK and so in theory should work for those who become resistance to the other BTK blockers due to a mutation in the C481 binding site, the leading known cause of resistance.

Stay strong.

We are all in this together.

Brian

cllsociety.org

bkoffman.blogspot.com

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...

Not what you're looking for?

You may also like...

Diagnosed with Monoclonal B-cell lymphocytosis (MBL) and scared!

I'm 41 year old with a 6 year history of Chronic Nonallergic Rhinitis causing polyps. After months...

YABTKi or Yet Another BTK inhibitor - the A to Z list of Bruton's Tyrosine Kinase Inhibitors for CLL following Ibrutinib's success

I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...

News about V+O and Acalabrutinib from EHA

Hi, The future of CLL therapy we believe will include fixed duration treatments of non-chemo drugs....

Time-Limited Triplet Emerges as a Potential Standard in Relapsed/Refractory CLL

Oncology live May 06, 2020 The time-limited triplet of umbralisib, ublituximab, and venetoclax...

A new kid on the block? Nemtabrutinib

Hi All, There is a new targeted drug in Clinical Trials that may offer a new treatment option for...